UGCG and nasopharyngeal carcinoma: The only therapy for NPC approved by the European Medical Association (EMA) is oral administration of the glucosylceramide synthase (GCS) inhibitor N-butyl-1-deoxynojirimycin (NB-DNJ, Zavesca) [7].